Please assess the completion status of the following clinical trial:

Trial Title: Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \</= 70 years~* Documented myeloma confirmed at protocol entry~* Adequate presence of \>/=2.0x10e6/kg cryopreserved CD34+ cells~* Adequate organ function~* Prior therapy is allowed as long as the organ function parameters are maintained and/or excessive radiation exposure is not produced~* Chemosensitivity~Exclusion Criteria:~* Uncontrolled infection~* Pregnant or lactating females~* Patients in \>/= very good partial response after initial primary non-transplant therapy and/or AHSCT1~* Patients unwilling to practice adequate forms of contraception if clinically indicated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Total Skeletal Irradiation (Type: EXPERIMENTAL): Three subjects determined to be eligible for study and agree to participate are assigned to receive 200 cGy of TSI-HT for 5 days. If this dose level is well tolerated in the first 3 subjects, the dose will be increased and given over 5 days. The dose will continue to be increased until the maximum toelrated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).